The Fosun and Hidea-backed stroke therapy technology developer has raised an eight-digit sum that will help advance its product pipeline.

The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.

Merck & Co backed a $14m series B for SAB Biotherapeutics, which is developing drugs for two forms of coronavirus including Covid-19.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.

UPMC's patient telemedicine service Curavi Health has completed a merger that enables its founding institution to retain an equity stake.

Ascension Ventures helped add $6m to a round for the telemedicine technology provider already featuring Cigna and MemorialCare Health.

Section 32 has led a $46.7m series B round that will support further development of the MIT spinout's biosensor-based diagnostics device.

Intermountain Ventures, already among the medical chatbot developer's customers, participated in a $13.6m round that took its total funding past $20m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.